Literature DB >> 32511113

Uninterrupted Anesthesia Support and Technique Adaptations for Patients Presenting for Electroconvulsive Therapy During the COVID-19 Era.

Venkatesan Thiruvenkatarajan, Ashok Dharmalingam1, Allysan Armstrong-Brown1, Alan Weiss2, Susan Waite3, Roelof Van Wijk.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32511113      PMCID: PMC7299118          DOI: 10.1097/YCT.0000000000000707

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.692


× No keyword cloud information.
Appeals have been made to deliver uninterrupted electroconvulsive therapy (ECT) services during the COVID-19 outbreak as the pandemic is likely to increase the mental health burden[1,2]. A recent report highlighted a bad outcome when the service had to be suspended halfway during a treatment course[3]. The need for ECT can be classified as elective, essential and urgent/emergency. Elective means that ECT is indicated if the patient is not at significant risk if ECT is not given: e.g. treatment resistant depression without the risk of suicide. Essential ECT is indicated when the patient is at significant risk if ECT is not given: e.g. depression with significant suicide risk or maintenance ECT when the patient is likely to relapse quickly when ECT is withdrawn. Urgent or emergency ECT is indicated when the patient is at high risk if ECT is not given: e.g. severe and or psychotic depression with dehydration and cachexia, malignant catatonia and manic delirium[2,4]. Anesthesiologists may either encounter known/suspected COVID-19 cases, or ward-nursed unsuspected patients who happen to be in close proximity to a positive case. Such a scenario has been recently described[3]. Aerosol/droplet dispersion is likely during the peri-ictal phase from airway manipulation, bag mask ventilation (BMV), cough and motor seizures. We highlight airway management principles for ECT in suspected as well as unsuspected COVID-19 patients, based on current guidelines and our practice adaptations. Known or suspected cases should be performed with full personal protective equipment precautions (as per local guidelines) in a negative pressure room if available. Patients should be briefed about the procedure and the attire worn by the staff to prevent an overwhelming impression. For co-operative patients, a surgical facemask should be applied during transfer. A dedicated anesthetic machine with a viral filter at the expiratory limb is preferable. Open anesthetic circuits such as the Bain’s modification of Mapleson D without viral filters is a common practice in resource-poor settings and are best avoided. BMV is generally discouraged for known/suspected COVID patients considering the possibility of a poor airway seal increasing the risk of aerosolization[5]. Also, it leaves the respiratory track and the upper airway open during the ictal phase. While tracheal intubation can achieve a near complete seal and limit aerosolization, the intubation and extubation process together with bucking on the endotracheal tube and maneuvers such as suctioning can increase the risk of aerosol and droplet dispersion. The latest expert opinion supports the use of supraglottic airways (SGAs) in known/suspected COVID patients when it is indicated[6]. Currently, evidence is lacking to support one device (SGA vs tracheal tubes) over the other during this pandemic[6]. SGA insertion and removal may be less aerosol generating than during tracheal intubation and extubation, and tracheal intubation is the procedure most associated with virus transmission[6]. These devices offer better seal pressure during assisted ventilation compared to the first generation devices, and may reduce aerosolization of viral particles[5,7]. For these reasons, a second generation SGA such as the i-gel® (taking due care to ensure a leak-free seal) may be a better option for airway management than standard practice in known/suspected COVID cases for ECT. The technique has many favorable features. First, a well-fitting device can offer a near complete seal of the oropharynx. Second, it negates the requirement for BMV, and can reduce proximity of the staff to the airway. Third, a closed circuit can be established (without disconnection) and maintained throughout the stimulus and seizure phase. Fourth, it facilitates smooth emergence. The gastric channel can be taped to prevent any droplet dispersion. Preoxygenation (< 6 L min -1) with a two-hand mask holding technique should commence using an anaesthetic face mask with a viral filter. An antisialagogue would help to reduce the secretions and droplet spread. Induction should be followed by administration of 1.5 mg/kg of succinylcholine, and a SGA should be inserted when appropriate. Gentle BMV prior to SGA insertion should be restricted only for hypoxia. Gentle positive pressure ventilation should commence after ensuring leak-free seal and establishing a closed circuit system. It may be better to avoid ventilation during facsiculations due to high esophageal pressures. During electro-stimulus application and seizure activity, a firm bite block should remain in-place; circuit should remain connected, adjustable pressure relief valve opened to zero, and ventilation ceased at end-expiration. Anaesthetic induction, SGA insertion and stimulus delivery can be done under a clear plastic tent, firmly encircled over the head and chest areas (Figure). This method may reduce aerosol/droplet dispersion and allows unobstructed monitoring of motor seizures. Synchronized ventilation should be commenced when appropriate and extubation performed under the tent and transitioned to oxygen delivering devices. Many patients who receive ECT feel claustrophobic and could become anxious if covered by sheets/tents. Special COVID intubating negative pressure chambers have been discussed on online/social media platforms. These chambers are transparent with a big surface area and projects away from the face and torso, and likely to be less disturbing to the patients. Supraglottic airway (i-gel®) with a viral filter and bite block in place and a clear plastic tent covering the airway and upper part of chest. The service is provided without any interruption at our (AD) institution, located in the state with highest prevalence of COVID-19 in the country at the time of this writing. There are suggestions that viral transmission is feasible through asymptomatic carriers, and viral loads could be similar between symptomatic and asymptomatic patients[8]. In areas with high prevalence, opinion from infectious disease experts should be considered in choosing an optimal technique. A practice change has been implemented for our routine cases. This involves airway management with i-gel® (with a viral filter), a second generation SGA device. Author’s preference of bite block is tightly rolled gauzes about 2 cm diameter. Antiemetics are warranted as post-ictal nausea can manifest in up to 25% of patients[9]. Self-limiting post-ictal agitation (with potential for droplets spread) can affect up to 10% of patients. In severe cases, small doses of benzodiazepines, propofol or dexmedetomidine can be used[10]. Policy makers must appreciate the role of ECT in reinstating quality of life for patients during the pandemic. As guidelines and clinical updates in the management of COVID-19 patients continue to evolve, locally adapted and updated recommendations are often the best resource.
  8 in total

Review 1.  Individualized Anesthetic Management for Patients Undergoing Electroconvulsive Therapy: A Review of Current Practice.

Authors:  Ethan O Bryson; Amy S Aloysi; Kate G Farber; Charles H Kellner
Journal:  Anesth Analg       Date:  2017-06       Impact factor: 5.108

2.  Staff safety during emergency airway management for COVID-19 in Hong Kong.

Authors:  Jonathan Chun-Hei Cheung; Lap Tin Ho; Justin Vincent Cheng; Esther Yin Kwan Cham; Koon Ngai Lam
Journal:  Lancet Respir Med       Date:  2020-02-24       Impact factor: 30.700

3.  Premedication with dexmedetomidine and midazolam attenuates agitation after electroconvulsive therapy.

Authors:  Ayse Mizrak; Senem Koruk; Suleyman Ganidagli; Mahmut Bulut; Unsal Oner
Journal:  J Anesth       Date:  2009-02-22       Impact factor: 2.078

Review 4.  Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic.

Authors:  Rashid N Lui; Sunny H Wong; Sergio A Sánchez-Luna; Gianluca Pellino; Steven Bollipo; Mei-Yin Wong; Philip W Y Chiu; Joseph J Y Sung
Journal:  J Gastroenterol Hepatol       Date:  2020-04-22       Impact factor: 4.029

Review 5.  Electroconvulsive therapy and its different indications.

Authors:  Thomas C Baghai; Hans-Jürgen Möller
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

6.  Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group.

Authors:  David J Brewster; Nicholas Chrimes; Thy Bt Do; Kirstin Fraser; Christopher J Groombridge; Andy Higgs; Matthew J Humar; Timothy J Leeuwenburg; Steven McGloughlin; Fiona G Newman; Chris P Nickson; Adam Rehak; David Vokes; Jonathan J Gatward
Journal:  Med J Aust       Date:  2020-05-01       Impact factor: 7.738

7.  Electroconvulsive Therapy During COVID-19: An Essential Medical Procedure-Maintaining Service Viability and Accessibility.

Authors:  Randall T Espinoza; Charles H Kellner; William V McCall
Journal:  J ECT       Date:  2020-06       Impact factor: 3.635

8.  Electroconvulsive Therapy in a Time of Coronavirus Disease.

Authors:  Phern Chern Tor; Adeline H H Phu; Doris S H Koh; Yee Ming Mok
Journal:  J ECT       Date:  2020-06       Impact factor: 3.692

  8 in total
  6 in total

1.  Electroconvulsive Therapy in Canada During the First Wave of COVID-19: Results of the "What Happened" National Survey.

Authors:  Ilya Demchenko; Daniel M Blumberger; Alastair J Flint; Melanie Anderson; Zafiris J Daskalakis; Karen Foley; Keyvan Karkouti; Sidney H Kennedy; Karim S Ladha; Jamie Robertson; Alon Vaisman; David Koczerginski; Sagar V Parikh; Venkat Bhat
Journal:  J ECT       Date:  2022-03-01       Impact factor: 3.692

2.  An Online Survey About Electroconvulsive Therapy in Japan During the COVID-19 Pandemic: Comparison of Early and Recent Stages.

Authors:  Risa Hirata; Hirotsugu Kawashima; Takashi Tsuboi; Ken Wada; Minoru Takebayashi; Taro Suwa
Journal:  Neuropsychiatr Dis Treat       Date:  2022-06-28       Impact factor: 2.989

3.  Effective Adaptation of Ventilation Maneuvers in Electroconvulsive Therapy Sessions During the Coronavirus Disease 2019 Pandemic.

Authors:  Aida de Arriba-Arnau; Antònia Dalmau Llitjos; Virginia Soria; José Manuel Menchón; Mikel Urretavizcaya
Journal:  J ECT       Date:  2021-06-01       Impact factor: 3.635

4.  Psychotropics and COVID-19: An analysis of safety and prophylaxis.

Authors:  H Javelot; C Straczek; G Meyer; C Gitahy Falcao Faria; L Weiner; D Drapier; E Fakra; P Fossati; S Weibel; S Dizet; B Langrée; M Masson; R Gaillard; M Leboyer; P M Llorca; C Hingray; E Haffen; A Yrondi
Journal:  Encephale       Date:  2021-09-02       Impact factor: 1.291

Review 5.  The Impact of COVID-19 on Brain Stimulation Therapy.

Authors:  Michael Justin Coffey; Suzanne Kerns; Sohag Sanghani; Lee Wachtel
Journal:  Psychiatr Clin North Am       Date:  2021-11-16

6.  Ventilation Adjustment in ECT During COVID-19: Voluntary Hyperventilation is an Effective Strategy.

Authors:  Aida de Arriba-Arnau; Antònia Dalmau Llitjos; Virginia Soria; Javier Labad; José Manuel Menchón; Mikel Urretavizcaya
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-20       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.